- Home
- PBT vs CRGX Comparison
PBT vs CRGX Comparison
Compare PBT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- CRGX
- Stock Information
- Founded
- PBT 1980
- CRGX 2021
- Country
- PBT United States
- CRGX United States
- Employees
- PBT N/A
- CRGX N/A
- Industry
- PBT Oil & Gas Production
- CRGX
- Sector
- PBT Energy
- CRGX
- Exchange
- PBT Nasdaq
- CRGX Nasdaq
- Market Cap
- PBT 558.4M
- CRGX 628.6M
- IPO Year
- PBT N/A
- CRGX 2023
- Fundamental
- Price
- PBT $11.10
- CRGX $3.70
- Analyst Decision
- PBT
- CRGX Hold
- Analyst Count
- PBT 0
- CRGX 7
- Target Price
- PBT N/A
- CRGX $4.67
- AVG Volume (30 Days)
- PBT 116.9K
- CRGX 1.9M
- Earning Date
- PBT 01-01-0001
- CRGX 03-20-2025
- Dividend Yield
- PBT 4.81%
- CRGX N/A
- EPS Growth
- PBT 25.21
- CRGX N/A
- EPS
- PBT 0.78
- CRGX N/A
- Revenue
- PBT $37,735,284.00
- CRGX N/A
- Revenue This Year
- PBT N/A
- CRGX N/A
- Revenue Next Year
- PBT N/A
- CRGX N/A
- P/E Ratio
- PBT $14.14
- CRGX N/A
- Revenue Growth
- PBT 25.46
- CRGX N/A
- 52 Week Low
- PBT $10.14
- CRGX $3.00
- 52 Week High
- PBT $14.58
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- PBT 39.41
- CRGX 20.88
- Support Level
- PBT $10.95
- CRGX $3.00
- Resistance Level
- PBT $11.41
- CRGX $3.88
- Average True Range (ATR)
- PBT 0.42
- CRGX 0.92
- MACD
- PBT -0.06
- CRGX -1.00
- Stochastic Oscillator
- PBT 15.05
- CRGX 5.99
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.